表紙
市場調査レポート

Eli Lilly and Companyの製品パイプライン分析

Eli Lilly and Company - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 240920
出版日 ページ情報 英文 242 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
Eli Lilly and Companyの製品パイプライン分析 Eli Lilly and Company - Product Pipeline Review - 2016
出版日: 2016年02月29日 ページ情報: 英文 242 Pages
概要

Eli Lilly and Companyは、米国を拠点とする製薬企業で、医薬品の創薬、開発、製造および販売を手掛けます。同社の製品ポートフォリオには、神経科学、内分泌系、腫瘍、心血管、動物医療など、様々な製品が存在します。

当レポートでは、Eli Lilly and Companyにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Eli Lilly and Companyの基本情報

Eli Lilly and Companyの概要

  • 主要情報
  • 企業情報

Eli Lilly and Company:R&Dの概要

  • 主な治療範囲

Eli Lilly and Company:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
  • アウトライセンス製品

Eli Lilly and Company:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
  • 治験段階にあるパイプライン製品
  • 初期段階にあるパイプライン製品

Eli Lilly and Company:薬剤プロファイル

  • cetuximab
  • dulaglutide
  • insulin glargine
  • ramucirumab
  • tadalafil
  • vancomycin
  • baricitinib
  • duloxetine hydrochloride DR
  • evacetrapib
  • insulin peglispro
  • ixekizumab
  • LY-2835219
  • necitumumab
  • solanezumab
  • tabalumab
  • teriparatide
  • edivoxetine
  • galunisertib
  • blosozumab
  • emibetuzumab
  • erteberel
  • gandotinib
  • icrucumab
  • LY-2090314
  • LY-2409021
  • LY-2495655
  • LY-2510924
  • LY-2606368
  • LY-2801653
  • LY-2928057
  • LY-2940094
  • LY-2944876
  • LY-2951742
  • LY-3015014
  • LY-3016859
  • olaratumab
  • pemetrexed disodium
  • ralimetinib mesylate
  • taladegib
  • LY-3053102
  • IMC-3C5
  • IMC-CS4
  • LY-2780301
  • LY-2787106
  • LY-2874455
  • LY-2922083
  • LY-2922470
  • LY-2969822
  • LY-2979165
  • LY-3002813
  • LY-3006072
  • LY-3009120
  • LY-3022859
  • LY-3023414
  • LY-3025876
  • LY-3039478
  • LY-3045697
  • LY-3050258
  • LY-3074828
  • LY-3084077
  • LY-3090106
  • LY-3108743
  • LY-3127760
  • LY-404039
  • TT-401
  • cercosporamide
  • CPZEN-45
  • LLY-2707
  • LSN-2463359
  • LSN-2535717
  • LSN-2814617
  • LY-2109761
  • LY-2607540
  • LY-2857785
  • LY-364937
  • LYTAK-1
  • 癌治療用モノクローナル抗体
  • ND-09759
  • 2型糖尿病および肥満症治療用ペプチド
  • 癌治療用二重特異性モノクローナル抗体
  • 2型糖尿病用多環性グアニジン誘導体
  • アルツハイマー病向けのベータセクレターゼを阻害する小分子、など

Eli Lilly and Company:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Eli Lilly and Company:最近のパイプライン動向

Eli Lilly and Company:休止中のプロジェクト

Eli Lilly and Company:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル

Eli Lilly and Company:企業発表

Eli Lilly and Company:本社と子会社の所在地

Eli Lilly and Company:主要製造設備

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07969CDB

Summary

Global Markets Direct's, 'Eli Lilly and Company - Product Pipeline Review - 2016', provides an overview of the Eli Lilly and Company's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Eli Lilly and Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Eli Lilly and Company
  • The report provides overview of Eli Lilly and Company including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Eli Lilly and Company's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Eli Lilly and Company's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Eli Lilly and Company's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Eli Lilly and Company
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Eli Lilly and Company's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Eli Lilly and Company Snapshot
    • Eli Lilly and Company Overview
    • Key Information
    • Key Facts
  • Eli Lilly and Company - Research and Development Overview
    • Key Therapeutic Areas
  • Eli Lilly and Company - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Eli Lilly and Company - Pipeline Products Glance
  • Eli Lilly and Company - Late Stage Pipeline Products
  • Eli Lilly and Company - Clinical Stage Pipeline Products
  • Eli Lilly and Company - Early Stage Pipeline Products
  • Eli Lilly and Company - Drug Profiles
    • baricitinib
    • duloxetine hydrochloride DR
    • ixekizumab
    • necitumumab
    • olaratumab
    • ramucirumab
    • cetuximab
    • abemaciclib
    • AMG-5041
    • insulin peglispro
    • LY-2951742
    • odelepran hydrochloride
    • solanezumab
    • tadalafil
    • galunisertib
    • blosozumab
    • edivoxetine hydrochloride
    • emibetuzumab
    • erteberel
    • icrucumab
    • insulin lispro U100
    • landogrozumab
    • LY-2510924
    • LY-2623091
    • LY-2874455
    • LY-2928057
    • LY-2944876
    • LY-3015014
    • LY-3016859
    • LY-3023414
    • LY-3074828
    • merestinib
    • prexasertib
    • ralimetinib mesylate
    • LY-2780301
    • LY-3039478
    • Biologic 6 for Diabetes
    • Biologic for Crohn's Disease
    • Biologic for Diabetic Nephropathy
    • Biologic for Hypoglycemia
    • Biologic for Lupus
    • Biologic for Neutrophilic Dermatosis
    • Biologic for Renal Anemia
    • dulaglutide
    • insulin lispro U200
    • LY-2599666
    • LY-2969822
    • LY-3002813
    • LY-3009120
    • LY-3022855
    • LY-3025876
    • LY-3041658
    • LY-3050258
    • LY-3076226
    • LY-3079514
    • LY-3090106
    • LY-3108743
    • LY-3114062
    • LY-3127760
    • LY-3127804
    • LY-3143753
    • LY-3154207
    • LY-3164530
    • LY-3185643
    • LY-3200327
    • LY-3202626
    • LY-3337641
    • LY-900014
    • Recombinant Protein for Parkinson's Disease
    • Small Molecule 4 for Diabetes
    • cercosporamide
    • CPZEN-45
    • LLY-2707
    • LSN-2463359
    • LSN-2535717
    • LSN-2814617
    • LY-2109761
    • LY-2607540
    • LY-2811376 + LY-3002813
    • LY-2857785
    • LY-344545
    • Monoclonal Antibody Conjugate 2 for Oncology
    • Monoclonal Antibody Conjugate 3 for Oncology
    • Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology
    • ND-09759
    • Small Molecule to Agonize TR-Beta for Dyslipidemia
    • Small Molecule to Antagonize mGlu5 for Pain
    • Drugs for Oncology
    • IC-87201
    • Monoclonal Antibodies for Undisclosed Indication
    • Small Molecule for Type 2 Diabetes
    • Small Molecule to Antagonize EP4 Receptor for Pain and Inflammation
    • Small Molecule to Inhibit MPGES-1 for Inflammation and Pain
  • Eli Lilly and Company - Pipeline Analysis
    • Eli Lilly and Company - Pipeline Products by Target
    • Eli Lilly and Company - Pipeline Products by Route of Administration
    • Eli Lilly and Company - Pipeline Products by Molecule Type
    • Eli Lilly and Company - Pipeline Products by Mechanism of Action
  • Eli Lilly and Company - Recent Pipeline Updates
  • Eli Lilly and Company - Dormant Projects
  • Eli Lilly and Company - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Eli Lilly and Company - Company Statement
  • Eli Lilly and Company - Locations and Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Eli Lilly and Company - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Eli Lilly and Company, Key Information
  • Eli Lilly and Company, Key Facts
  • Eli Lilly and Company - Pipeline by Indication, 2016
  • Eli Lilly and Company - Pipeline by Stage of Development, 2016
  • Eli Lilly and Company - Monotherapy Products in Pipeline, 2016
  • Eli Lilly and Company - Combination Treatment Modalities in Pipeline, 2016
  • Eli Lilly and Company - Partnered Products in Pipeline, 2016
  • Eli Lilly and Company - Partnered Products/ Combination Treatment Modalities, 2016
  • Eli Lilly and Company - Out-Licensed Products in Pipeline, 2016
  • Eli Lilly and Company - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Eli Lilly and Company - Pre-Registration, 2016
  • Eli Lilly and Company - Filing rejected/Withdrawn, 2016
  • Eli Lilly and Company - Phase III, 2016
  • Eli Lilly and Company - Phase II, 2016
  • Eli Lilly and Company - Phase I, 2016
  • Eli Lilly and Company - Preclinical, 2016
  • Eli Lilly and Company - Discovery, 2016
  • Eli Lilly and Company - Pipeline by Target, 2016
  • Eli Lilly and Company - Pipeline by Route of Administration, 2016
  • Eli Lilly and Company - Pipeline by Molecule Type, 2016
  • Eli Lilly and Company - Pipeline Products by Mechanism of Action, 2016
  • Eli Lilly and Company - Recent Pipeline Updates, 2016
  • Eli Lilly and Company - Dormant Developmental Projects,2016
  • Eli Lilly and Company - Discontinued Pipeline Products, 2016
  • Eli Lilly and Company, Subsidiaries
  • Eli Lilly and Company, Key Manufacturing Facilities

List of Figures

  • Eli Lilly and Company - Pipeline by Top 10 Indication, 2016
  • Eli Lilly and Company - Pipeline by Stage of Development, 2016
  • Eli Lilly and Company - Monotherapy Products in Pipeline, 2016
  • Eli Lilly and Company - Partnered Products in Pipeline, 2016
  • Eli Lilly and Company - Out-Licensed Products in Pipeline, 2016
  • Eli Lilly and Company - Pipeline by Top 10 Target, 2016
  • Eli Lilly and Company - Pipeline by Route of Administration, 2016
  • Eli Lilly and Company - Pipeline by Molecule Type, 2016
  • Eli Lilly and Company - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top